Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.059 | Exploring the Experiences and Perceptions of Non-Invasive Ventilation among Patients with Chronic Obstructive Pulmonary Disease and Family Members: A Qualitative Study | Dr. CHAN Helen Yue Lai |
| 2017.019 | Training needs assessment of Nurse Preceptors in general hospital |
Dr. CHAN Helen Yue Lai 陳裕麗 |
| 2017.099 | Promoting person-centred approach advance care planning in long-term care setting: A pilot study | Dr. CHAN Helen Yue Lai |
| 2011.501 | A quasi-experimental study of a skin care protocol on improving skin hydration and reducing skin tear in geriatric patients | Dr. Chan Helen Yue Lai |
| 2024.341 | JC Brain Health: Jockey Club Dementia Screening and Community Support Project (DSCS) - Part 2. A waitlist randomised controlled trial | Prof. CHAN Helen Yue Lai |
| 2023.616 | JC Brain Health: Jockey Club Dementia Screening and Community Support Project (DSCS) - Part 1. A two-arm pragmatic randomised controlled trial | Prof. CHAN Helen Yue Lai |
| 2013.310 | Evidence-based foot and toenail care protocol for patients in long term care setting | Prof. Chan Helen Yue Lai |
| 2016.139 | Exploring moral distress and perceived constraints among nurses | Dr. CHAN Helen Yue Lai |
| 2010.236 | Week 24 response and long-term outcomes of lamivudine (Zeffix) therapy in patients with chronic hepatitis B - A prospective cohort study | Professor Chan Henry |
| 2009.106 | A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients with HBeAg Positive Chronic Hepatitis B from the Original Study WV19432 (NEPTUNE) | Prof. Chan Henry L.Y. |
| 2012.295 | An exploratory evaluation of interleukin 28B(IL28B) genotype, protein and RNA biomarkers in serum samples (stored, already obtained from completed studies) from subjects with HBE-antigen positive or negative chronic hepatitis B, who have completed therapy | Prof. Chan Henry Lik Yuen |
| 2009.105 | A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of Lead-in Telbivudine for 24 Weeks with or without Tenofovir Treatment Intensification in Adult Patients with HBeAg-positive Chronic Hepatitis B | Prof. Chan Henry Lik Yuen |
| 2003.382 | A Randomized, Double-blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | Prof. CHAN Henry Lik Yuen |
| 2013.410 | A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment-Na_ve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2013.605 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination with Entecavir in Patients with Chronic Hepatitis B Virus (HBV) Infection, followed by a two-dose open label cohort and an open label single dose cohort in treatment naïve patients | Prof. CHAN Henry Lik Yuen |
| 2010.336 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Prof. CHAN Henry Lik Yuen |
| 2009.404 | A pharmacokinetic/pharmacodynamic evaluation of ABF656 in subjects with chronic hepatitis B, eAg+, infection | Prof. Chan Henry Lik Yuen |
| 2011.233 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Prof. CHAN Henry Lik Yuen |
| 2011.284 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Prof. Chan Henry Lik Yuen |
| 2013.264 | A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored Alisporivir-studies for chronic Hepatitis C patients | Prof. Chan Henry Lik Yuen |
| 2018.313 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-506, an HBV Capsid Inhibitor, in Healthy Subjects and HBV-DNA Positive Subjects with Chronic HBV Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2018.104 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2010.071 | Presictive value of week 24 response for long-term outcomes of entecavir therapy in patients with chronic hepatitis B | Prof. CHAN Henry Lik Yuen |
| 2012.216 | Risk of advanced colorectal neoplasm in patients with non-alcoholic fatty liver disease | Prof. CHAN Henry Lik Yuen |
| 2009.161 | A Study on the Sustainability of Response to Anti-Viral Agents in Chronic Hepatitis B | Prof. Chan Henry Lik Yuen |
| 2009.487 | Evaluation of 3' deleted HBx mutant as a serum marker to predict hepatocellular carcinoma in chronic hepatitus B | Prof. CHAN Henry Lik Yuen |
| 2009.242 | Viral Genomic Determinatns of Liver Fibrosis in Chronic Hepatitis B | Prof. CHAN Henry Lik Yuen |
| 2010.144 | The impact of drug resistance testing in the management of patients with chronic hepatitis B on antiviral therapy - A retrospective study and survey | Prof. CHAN Henry Lik Yuen |
| 2009.438 | Association of serum hepatitis B surface antigen level with the risk of hepatocellular carcinoma | Prof. CHAN Henry Lik Yuen |
| 2009.250 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600mg and tenofovir disproxil fumarate 300mg in combination or telbivudine 600mg or tenofovir disproxil furmarate 300mg monothe | Prof. Chan Henry Lik Yuen |
| 2009.318 | Health Related Quality of Life in Patients with Chronic Hepatitis C in Hong Kong | Prof. CHAN Henry Lik Yuen |
| 2017.197 | Kinetics of Hepatitis B core-related Antigen (HBcrAg) in Untreated and Nucleos(t)ide Analogue Treated Chronic Hepatitis B |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2015.596 | Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir combination with and without ribavirin in a diverse population of genotype 1 chronic hepatitis C patients in Hong Kong |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.350 | A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic Hepatitis C Virus GT5 or GT6 Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2015.189 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2015.190 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2017.270 | A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.353 | Performance of Fibrometer™ V in patients with chronic hepatitis B (HBV) | Prof. CHAN Henry Lik Yuen |
| 2016.369 | Sample Collection for the Evaluation of Elecsys® PIVKA-II, AFP-L3 and AFP |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.416 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV | Prof. CHAN Henry Lik Yuen |
| 2014.415 | Prospective Sample Collection - Evaluation of novel markers for early detection of Hepatocellular Carcinoma (HCC) - | Prof. CHAN Henry Lik Yuen |
| 2015.622 | A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.034 | A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2015.703 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.668 | An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2016.529 | Cells of monocytic origin as surrogate marker for individual drug effects and hepatotoxicity |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.658 | A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region | Prof. CHAN Henry Lik Yuen |
| 2017.530 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.190 | A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.198 | A SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY STUDY OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS (3) PATIENTS WITH CHRONIC HEPATITIS B |
Prof. CHAN Henry Lik Yuen 陳力元 |
Page 51 of 289.